Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer

Abstract

Background

This study provides an indirect treatment comparison of ribociclib combined with non-steroidal aromatase inhibitors and ovarian function suppression (ribociclib + NSAI + OFS) vs. a frequently used treatment option in German clinical routine (tamoxifen ± OFS) in premenopausal patients with HR-positive (HR+), HER2-negative (HER2−) early breast cancer (BC).

Material and Methods

Data on premenopausal women treated with ribociclib and tamoxifen were derived from the NATALEE clinical trial (NCT03701334) and the retrospective German data collection CLEAR-B, respectively. NATALEE trial eligibility criteria were applied to the CLEAR-B dataset. Standardized mortality ratio weights were used for propensity score (PS) adjustment to balance study populations. All hazard ratios (HR) were calculated based on a 4-year-observation period for both treatment arms. Effectiveness endpoints comprised invasive and distant disease-free survival (iDFS, dDFS), recurrence-free survival (RFS), and overall survival (OS). Safety-related endpoints were treatment termination (TT) and toxicity-related TT (TTtox). For safety comparisons, the ribociclib arm was divided into groups that discontinued ribociclib + NSAI + OFS or ribociclib only.

Results

Significant beneficial effects favoring ribociclib + NSAI + OFS (n = 1115) over tamoxifen ± OFS (n = 822) were observed for all effectiveness outcomes (iDFS [HR = 0.5 (95% CI 0.35; 0.71); p < 0.01]; dDFS [HR = 0.52 (95% CI 0.35; 0.77); p = 0.01], RFS [HR = 0.42 (95% CI 0.29; 0.62); p < 0.01], OS [HR = 0.34 (95% CI 0.18; 0.63); p = 0.01]) during the 4-year-observation period. The effect of early treatment discontinuation showed no significant differences between ribociclib + NSAI + OFS and tamoxifen ± OFS (TT-a: HR = 1.2 [95% CI: 0.71; 2.01], p = 0.48; TTtox-a: HR = 0.54 [95% CI 0.22; 1.30], p = 0.23).

Conclusion

In this retrospective analysis, ribociclib + NSAI + OFS demonstrated advantages across all effectiveness endpoints, including OS, in premenopausal women with HR+, HER2− early BC, without increasing overall treatment discontinuation rates compared to tamoxifen ± OFS.

Zusammenfassung

Hintergrund

Die vorliegende Studie liefert einen indirekten Behandlungsvergleich von Ribociclib kombiniert mit nichtsteroidalen Aromatasehemmern und ovarieller Funktionsunterdrückung (Ribociclib + NSAI + OFS) mit einer oft in der täglichen klinischen Praxis in Deutschland eingesetzten Behandlungsoption (Tamoxifen ± OFS) bei prämenopausalen Patientinnen mit HR-positivem (HR+), HER2-negativem (HER2−) Brustkrebs im Frühstadium (BC).

Material und Methoden

Die Daten der mit Ribociclib und Tamoxifen behandelten prämenopausalen Frauen wurden der klinischen NATALEE-Studie (NCT03701334) bzw. der retrospektiven deutschen CLEAR-B-Datensammlung entnommen. Die Einschlusskriterien der NATALEE-Studie wurden auf den CLEAR-B-Datensatz angewendet. Gewichtete standardisierte Mortalitätsverhältnisse wurden zur Adjustierung des Propensitäts-Scores (PS) eingesetzt, um die Studienpopulationen anzugleichen. Alle Hazard Ratios (HR) wurden für beide Behandlungsarme kalkuliert und bezogen sich auf einen Beobachtungszeitraum von 4 Jahren. Die Effektivitätsendpunkte waren invasives und fernes krankheitsfreies Überleben (iKFÜ, fKFÜ), rezidivfreies Überleben (RFÜ) und Gesamtüberleben (GÜ). Die sicherheitsbezogenen Endpunkte waren Beendigung der Behandlung („Treatment Termination“ [TT]) sowie toxizitätsbezogene TT (TTtox). Für den Sicherheitsvergleich wurde der Ribociclib-Arm weiter in eine Gruppe, welche die Behandlung mit Ribociclib + NSAI + OFS abbrach, und eine Gruppe, die nur Ribociclib erhielt, unterteilt.

Ergebnisse

Während des 4-jährigen Beobachtungszeitraums wurden erhebliche positive Effekte zugunsten von Ribociclib + NSAI + OFS (n = 1115) im Vergleich zu Tamoxifen ± OFS (n = 822) für alle Effektivitäts-Outcomes festgestellt (iKFÜ [HR = 0,5 (95%-KI 0,35; 0,71); p < 0,01]; fKFÜ [HR = 0,52 (95%-KI 0,35; 0,77); p = 0,01], RFÜ [HR = 0,42 (95%-KI 0,29; 0,62); p < 0,01], GÜ [HR = 0,34 (95%-KI 0,18; 0,63); p = 0,01]). Es gab keine signifikanten Unterschiede zwischen Ribociclib + NSAI + OFS und Tamoxifen ± OFS bezüglich der Auswirkungen eines frühen Behandlungsabbruchs (TT-a: HR = 1,2 [95%-KI: 0,1; 2,01], p = 0,48; TTtox-a: HR = 0,54 [95%-KI 0,22; 1,30], p = 0,23).

Schlussfolgerung

In dieser retrospektiven Analyse wies Ribociclib + NSAI + OFS klare Vorteile in Bezug auf alle Effektivitätsendpunkte einschließlich des GÜ bei prämenopausalen Frauen mit HR+/HER2− Brustkrebs im Frühstadium auf, ohne dass die allgemeinen Behandlungsabbruchraten verglichen mit Tamoxifen ± OFS anstiegen.

Keywords

ribociclib - indirect treatment comparison - HR-positive - HER2-negative - early breast cancer

Schlüsselwörter

Ribociclib - indirekter Behandlungsvergleich - HR-positiv - HER2-negativ - Brustkrebs im Frühstadium

Publikationsverlauf

Eingereicht: 21. Januar 2025

Angenommen nach Revision: 14. März 2025

Artikel online veröffentlicht:
04. April 2025

• References

• 1 Ye H, Lin G, Wang X. A narrative review: research progress of adjuvant intensive endocrine therapy for early breast cancer. Transl Breast Cancer Res 2024; 5: 20
• 2 Loibl S, André F, Bachelot T. et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2024; 35: 159-182
• 3 Pan H, Gray R, Braybrooke J. et al. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med 2017; 377: 1836-1846
• 4 Pistilli B, Lohrisch C, Sheade J. et al. Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast Cancer. Am Soc Clin Oncol Educ Book 2022; 42: 1-13
• 5 Fasching P, Aktats B, Hübner H. CLEAR-B – Adjuvant therapy effectiveness in patients with primary breast cancer: A retrospective registry study (P4–11–12). San Antonio, TX, USA: San Antonio Breast Cancer Symposium; 2024
• 6 Hammond MEH, Hayes DF, Dowsett M. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795
• 7 AWMF. Interdisziplinäre S3-Leitlinie für die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 2021 Zugriff am 17. Februar 2025 unter: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Mammakarzinom_4_0/Version_4.4/LL_Mammakarzinom_Langversion_4.4.pdf
• 8 Schneeweiss A, Bauerfeind I, Fehm T. et al. Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. Breast Care (Basel) 2020; 15: 608-618
• 9 Hunter RJ, Park J, Asprer KJ. et al. Updated Review Article: Cyclin-Dependent Kinase 4/6 Inhibitor Impact, FDA Approval, and Resistance Pathways. J Pharm Technol 2023; 39: 298-308
• 10 Turner NC, Ro J, André F. et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 373: 209-219
• 11 Loibl S, Turner NC, Ro J. et al. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist 2017; 22: 1028-1038
• 12 Goetz MP, Toi M, Campone M. et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35: 3638-3646
• 13 Hortobagyi GN, Stemmer SM, Burris HA. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738-1748
• 14 Slamon DJ, Neven P, Chia S. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol 2018; 36: 2465-2472
• 15 Finn RS, Martin M, Rugo HS. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925-1936
• 16 O’Keefe K, Desai NV, Tan AR. Practical Guidance on Abemaciclib in Combination with Adjuvant Endocrine Therapy for Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative High-Risk Early Breast Cancer. Breast Cancer (Dove Med Press) 2024; 16: 517-527
• 17 Johnston SRD, Toi M, O’Shaughnessy J. et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023; 24: 77-90
• 18 Parati MC, Pedersini R, Perego G. et al. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection. Breast Cancer (Dove Med Press) 2022; 14: 101-111
• 19 Slamon D, Lipatov O, Nowecki Z. et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med 2024; 390: 1080-1091
• 20 Stanciu I-M, Parosanu AI, Nitipir C. An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer-A Systematic Review of Randomized Phase II and III Clinical Trials. Biomolecules 2023; 13: 1422
• 21 ClinicalTrials.gov. A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2− Early Breast Cancer (NATALEE). Zugriff am 06. November 2024 unter: https://clinicaltrials.gov/study/NCT03701334%23more-information
• 22 Institut für Frauengesundheit. Cancer Landscape – Early Adjuvant Retrospective Registry – Breast Cancer (CLEAR-B). Zugriff am 28. November 2024 unter: https://clear-b.de/%23about
• 23 Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ 2019; 367: l5657
• 24 Schaafsma E, Zhang B, Schaafsma M. et al. Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use. Breast Cancer Res 2021; 23: 74
• 25 Ohnstad HO, Borgen E, Falk RS. et al. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. Breast Cancer Res 2017; 19: 120
• 26 Xu Y, Qi Y, Lu Z. et al. Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer. Cancer Biol Ther 2024; 25: 2405060
• 27 Jung W, Kim K, Moon B-I. Treatment Outcomes according to the EndoPredict Score in ER-Positive, HER2-Negative Early Breast Cancer. Breast Care (Basel) 2022; 17: 561-566
• 28 ECOG Cancer Research Group. ECOG Performance Status Scale. Zugriff am 13. November 2024 unter: https://ecog-acrin.org/resources/ecog-performance-status/%23
• 29 Hudis CA, Barlow WE, Costantino JP. et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007; 25: 2127-2132
• 30 Leyrat C, Seaman SR, White IR. et al. Propensity score analysis with partially observed covariates: How should multiple imputation be used?. Stat Methods Med Res 2019; 28: 3-19
• 31 Morgan CJ. Landmark analysis: A primer. J Nucl Cardiol 2019; 26: 391-393
• 32 Park-Simon T-W, Müller V, Jackisch C. et al. Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023. Breast Care (Basel) 2023; 18: 289-305
• 33 Nabieva N, Altmann F, Apel K. et al. The Endocrine Treatment Landscape for Patients with HR+ HER2− Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy – A Real-World Analysis. Geburtshilfe Frauenheilkd 2023; 83: 1127-1137
• 34 Ma L, Yang B, Wu J. Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes. Cancer Treat Rev 2024; 129: 102770
• 35 Mueller V, Aktas B, Huebner H. et al. Adjuvant therapy effectiveness in patients with primary breast cancer: A retrospective registry study to evaluate endocrine therapy strategies and outcomes for premenopausal primary breast cancer patients at intermediate and high risk of recurrence. 2024 Zugriff am 02. April 2025 unter: https://clear-b.de/downloads/sabcs-poster.pdf
• 36 Francis PA, Pagani O, Fleming GF. et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 2018; 379: 122-137
• 37 EBCTCG. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 2022; 23: 382-392
• 38 Gluz O, Christgen M, Nitz U. et al. Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n = 4,334). Cancer Research 2024; 84: LBO1–05
• 39 Law E, Gavanji R, Walsh S. et al. Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points. J Comp Eff Res 2022; 11: 109-120
• 40 Zhao JJ, Fong KY, Chan YH. et al. Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2− Metastatic Breast Cancer. Cancers (Basel) 2023; 15: 4558
• 41 Chang M, Balser H, Roach JM. et al. Innovative strategies, statistical solutions and simulations for modern clinical trials. (Chapman & Hall/CRC Biostatistics Series; ). Boca Raton, London, New York: CRC Press Taylor & Francis Group; 2019